NASDAQ:BGNE - Beigene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$166.09 +0.75 (+0.45 %)
(As of 07/16/2018 02:46 AM ET)
Previous Close$166.09
Today's Range$160.68 - $168.29
52-Week Range$65.58 - $220.10
Volume229,544 shs
Average Volume319,547 shs
Market Capitalization$8.93 billion
P/E Ratio-74.48
Dividend YieldN/A
Beigene logoBeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of targeted therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317; and with Merck KGaA to research and develop on BGB-290 and BGB-283. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.12
Current Ratio11.18
Quick Ratio11.12


Trailing P/E Ratio-74.48
Forward P/E Ratio-19.07
P/E GrowthN/A

Sales & Book Value

Annual Sales$238.39 million
Price / Sales37.46
Cash FlowN/A
Price / CashN/A
Book Value$15.02 per share
Price / Book11.06


EPS (Most Recent Fiscal Year)($2.23)
Net Income$-93,100,000.00
Net MarginsN/A
Return on Equity-19.12%
Return on Assets-13.75%


Outstanding Shares53,760,000
Market Cap$8,929.83

The Truth About Cryptocurrencies

Beigene (NASDAQ:BGNE) Frequently Asked Questions

What is Beigene's stock symbol?

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

How were Beigene's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) issued its quarterly earnings data on Wednesday, May, 9th. The company reported ($2.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.62) by $0.41. The company earned $32.54 million during the quarter, compared to analysts' expectations of $16.88 million. During the same period in the prior year, the company earned ($1.27) EPS. View Beigene's Earnings History.

When is Beigene's next earnings date?

Beigene is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Beigene.

What price target have analysts set for BGNE?

8 equities research analysts have issued 1 year price targets for Beigene's shares. Their predictions range from $86.00 to $225.00. On average, they anticipate Beigene's stock price to reach $170.1667 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price. View Analyst Ratings for Beigene.

What is the consensus analysts' recommendation for Beigene?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Beigene stock?

Here are some recent quotes from research analysts about Beigene stock:
  • 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (7/10/2018)
  • 2. Maxim Group analysts commented, "BeiGene announced the commercial availability of Celgene’s VIDAZA. Recall that VIDAZA is an injectable nucleoside metabolic inhibitor for patients with Intermediate-2/high-risk myelodysplastic syndrome (MDS), AML with 20-30% bone marrow blasts and chronic myelomonocyte leukemia (CMML). The asset is the third product in BeiGene’s China commercial portfolio along with Abraxane and Revlimid and positions BeiGene to be a leader in the oncology space in China." (2/7/2018)

Who are some of Beigene's key competitors?

Who are Beigene's key executives?

Beigene's management team includes the folowing people:
  • Mr. John V. Oyler, Founder, Chairman and Chief Exec. Officer (Age 50)
  • Dr. Heng Liang Ph.D., Chief Financial Officer and Chief Strategy Officer (Age 55)
  • Dr. Amy C. Peterson M.D., Chief Medical Officer of Immuno-Oncology (Age 51)
  • Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 45)
  • Mr. Ji Li, Adviser to CEO Office (Age 50)

When did Beigene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Has Beigene been receiving favorable news coverage?

Press coverage about BGNE stock has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Beigene earned a news impact score of 0.09 on Accern's scale. They also assigned news articles about the company an impact score of 45.51 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Beigene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Beigene's stock price today?

One share of BGNE stock can currently be purchased for approximately $166.09.

How big of a company is Beigene?

Beigene has a market capitalization of $8.93 billion and generates $238.39 million in revenue each year. The company earns $-93,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Beigene employs 900 workers across the globe.

How can I contact Beigene?

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected]

MarketBeat Community Rating for Beigene (NASDAQ BGNE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  447
MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.